Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome

Acute Coronary Syndrome Clinical Trial

— AReMIS  

Official title:

Study on the Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01952392
• Other study ID #: NIS-CFR-BRI-2012/1
• Status: Completed
• Phase: N/A
• First received: August 21, 2013
• Last updated: February 23, 2017
• Start date: October 2013
• Est. completion date: March 2016

Study information

• Verified date: February 2017
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome

Description:

AReMIS (Antiplatelet and Recurrent Myocardial Infarction Study) To compare the relative risk of new myocardial infarction (recurrent myocardial infarction or 'rMI') in patients with a history of acute coronary syndrome ('ACS': unstable angina or myocardial infarction), using ticagrelor, clopidogrel or prasugrel (if applicable) or none of these treatments, where aspirin is considered a covariate.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4992
• Est. completion date: March 2016
• Est. primary completion date: March 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 130 Years

Eligibility

Inclusion Criteria:

Patients aged 18 years or more, both genders, with an acute coronary syndrome (ACS), agreed to participate and able to respond to an interview in French and/or providing the details of an alternative replier (proxy) if necessary.

No Exclusion Criteria.

Related Conditions & MeSH terms

• Acute Coronary Syndrome
• Syndrome

Locations

Country	Name	City	State
France	Research Site	Paris

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Medical information	History of coagulation and vascular disorders History of cerebrovascular accidents Cardiovascular risk factors	At baseline visit
Primary	Drug exposure	Current exposure: within 24 hours (before date of recurrent MI). Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.	Current
Primary	Drug exposure	Recent exposure: in the week (7 days) preceding the recurrent MI. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.	Recent
Primary	Drug exposure	Past exposure: more than a week (7 days) before the recurrent MI and until the ACS index. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.	Past
Secondary	Other medical events of interest	rMI, stroke, bleeding, death	During follow-up (up to 12 months)

External Links

•   CSR_Synopsis